Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 14/20 | 0.60 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.34 |
| ▸ | KCNN3 | Q9UGI6 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20448948 | 0.79 | PI4KB (0.56) | PDE10API4KBKDM4EALDH1A1MAPT | |
| SCHEMBL20533909 | 0.77 | PI4KB (0.36) | PDE10API4KBKDM4EALDH1A1MAPT | |
| SCHEMBL20533935 | 0.76 | CRHR1 (0.48) | PDE10API4KBKDM4EALDH1A1MAPT | |
| SCHEMBL20533911 | 0.76 | PDE10A (0.40) | PDE10API4KBKDM4EALDH1A1MAPT | |
| SCHEMBL20533900 | 0.75 | PI4KB (0.51) | PDE10API4KBKDM4EALDH1A1MAPT | |
| SCHEMBL20533593 | 0.72 | PDE10A (0.36) | PDE10AALDH1A1 | |
| SCHEMBL20533923 | 0.71 | PI4KB (0.54) | PI4KBKCNN3 | |
| SCHEMBL20533908 | 0.69 | MAPT (0.45) | PDE10AKDM4EALDH1A1MAPTRAB9A | |
| SCHEMBL14726823 | 0.68 | PDE10A (0.52) | PDE10ANR1I2CYP3A4CYP2D6 | |
| SCHEMBL20533663 | 0.68 | KMT2A (0.43) | CYP3A4KDM4EALDH1A1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180298009-A1 | Fused Pyrazole Derivatives As Kinase Inhibitors | UCB BIOPHARMA SPRL (BE) | 2018-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180298009-A1 | Fused Pyrazole Derivatives As Kinase Inhibitors | PI4KA, PI4K2B, PI4KB | PDE10A 1665/4885NR1I2 562/4885CYP3A4 592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.